arsenic has been researched along with B-Cell Lymphoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goel, A; Spitz, DR; Weiner, GJ | 1 |
| Giri, U; Kala, SV; Lieberman, MW; Story, MD; Terry, NH | 1 |
| Chen, L; Chen, SY; Li, QY; Xu, XP; Xu, XW; Yi, K; Zhou, F | 1 |
| Duan, Y; Li, HM; Liu, H; Yu, MJ; Zhang, XM | 1 |
| Au, WY; Fong, BM; Kwong, YL; Tam, S; Wan, TS; Yip, SF | 1 |
| Arora, M; Kaul, D; Sharma, M; Sharma, S | 1 |
| Ganapathy, S; Ha, CS; Li, X; Su, H; Yuan, ZM | 1 |
1 review(s) available for arsenic and B-Cell Lymphoma
| Article | Year |
|---|---|
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Oxides; Pyrazines; Radiotherapy | 2012 |
6 other study(ies) available for arsenic and B-Cell Lymphoma
| Article | Year |
|---|---|
Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Survival; Cloning, Molecular; Drug Resistance, Neoplasm; Flow Cytometry; Glutathione; Glutathione Transferase; Humans; Lymphoma, B-Cell; Membrane Potentials; Mice; Mitochondria; Oxides | 2005 |
[Effects of dexamethasone on arsenic trioxide induced apoptosis, NF-kappaB activation and gene expression in lymphoma cell line].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dexamethasone; Drug Interactions; Glucocorticoids; Humans; Immunohistochemistry; Lymphoma, B-Cell; Matrix Metalloproteinase 9; NF-kappa B; Oxides; Vascular Endothelial Growth Factor A | 2005 |
[Inhibited proliferation of B-lymphoma Raji cells and down-regulated expression of VEGF by arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Down-Regulation; Humans; Lymphoma, B-Cell; Oxides; RNA, Messenger; Vascular Endothelial Growth Factor A | 2006 |
Second hematological malignancies during arsenic trioxide therapy of B-cell lymphomas.
Topics: Aged; Arsenic Trioxide; Arsenicals; Female; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Male; Neoplasms, Second Primary; Oxides | 2009 |
Regulation of cellular Cyclin D1 gene by arsenic is mediated through miR-2909.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic; B-Cell Lymphoma 3 Protein; Cell Line, Tumor; Cell Transformation, Neoplastic; Deubiquitinating Enzyme CYLD; Genes, bcl-1; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Leukocytes, Mononuclear; Lymphoma, B-Cell; MicroRNAs; Protein Biosynthesis; Proto-Oncogene Proteins; Repressor Proteins; Sp1 Transcription Factor; Transcription Factors; Tumor Suppressor Proteins | 2013 |
p53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Arsenic; Biomarkers; Bone Marrow; Bone Marrow Cells; DNA Damage; Female; Genes, p53; Glucose Transporter Type 1; Glucose Transporter Type 3; Heterografts; Histones; In Situ Nick-End Labeling; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Radiation Dosage; Radiation Injuries, Experimental; Radiation Tolerance; Radiation-Protective Agents; Radioimmunotherapy; Transcriptional Activation; Yttrium Radioisotopes | 2015 |